期刊文献+

卵巢癌患者卵巢血流参数及组织MiR、KLK的变化 被引量:2

Observation on the change of ovarian blood flow parameters and tissue MiR,KLK of patients with ovarian carcinoma
下载PDF
导出
摘要 目的:观察及探讨卵巢癌患者卵巢血流参数及组织微小RNA(MiR)、组织激肽释放酶(KLK)的变化情况。方法:选取本院收治的66例卵巢癌患者为观察组,另以同期的66例卵巢良性肿瘤患者为对照组,然后将两组的卵巢血流参数及组织MiR、KLK表达情况进行比较,比较观察组中不同分期卵巢癌患者的上述检测项目。结果:观察组的卵巢血流收缩期峰值流速(PSV)高于对照组,阻力指数(RI)及搏动指数(PI)均低于对照组,组织MiR表达低于对照组,KLK则高于对照组,且观察组中不同分期卵巢癌者的上述检测结果之间比较,差异均具有统计学意义(P均<0.05)。结论:卵巢癌患者卵巢血流参数及组织MiR、KLK的变化较大,且上述指标对于卵巢癌分期也有较高的诊断价值。 Objective:To observe and investigate changes of ovarian blood flow parameters and tissue MiR,KLK of patients with ovarian carcinoma.Methods:A total of 66 patients with ovarian carcinoma treated in our hospital were selected as observation group,66 patients with benign ovarian tumor at the same time were enrolled as control group,then the ovarian blood flow parameters and tissue MiR,KLK expression of two groups were analyzed and compared,then those detection items of observation group with different stages of ovarian carcinoma were compared.Results:The ovarian blood flow PSV of observation group was higher than that of control group,RI and PI were lower than those of control group,tissue MiR expression were lower than those of control group,KLK were higher than those of control group,and those detection results of patients with different stages of ovarian carcinoma in the observation group were significantly different too(Pall〈0.05).Conclusion:Change of ovarian blood flow parameters and MiR,KLK in tissues of patients with ovarian carcinoma are great indicating they can be used for judging stages of ovarian carcinoma.
作者 王海燕 林薇
出处 《海南医学院学报》 CAS 2014年第10期1394-1396,共3页 Journal of Hainan Medical University
基金 湖北省武汉市科技局基金(20182877223)~~
关键词 卵巢癌 卵巢血流参数 微小RNA 组织激肽释放酶 Ovarian carcinoma Ovarian blood flow parameters Tissue MiR KLK
  • 相关文献

参考文献10

二级参考文献87

  • 1徐卫,李建勇,陆凤翔.微小RNA及其在恶性淋巴增殖性疾病中作用的研究进展[J].中国实验血液学杂志,2006,14(4):840-844. 被引量:4
  • 2张晶,张淑兰.KLK7基因与妇科肿瘤的研究进展[J].国外医学(妇产科学分册),2007,34(3):171-173. 被引量:2
  • 3Shaw JL,Diamandis EP. Distribution of 15 Human Kallikreins in Tissues and Biological Fluids[J]. Clin Chem, 2007,53 (8) : 1423-1432.
  • 4Sappino AP, Busso N, Belin D, et al. Increase of uroklnase-type plasminogen activator gene expression in human lung and breast carcinomasl[J]. Cancer Res, 1987,47 : 4043-4046.
  • 5White NM, Mathews M, Yousef GM, et al. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma[J]. Br J Cancer, 2009,101(7):1107-1113.
  • 6Ni X, Zhang W, Huang KC, et al. Characterization of human kallikrein 6/protease M expression in ovarian cancer[J]. Br J Cancer, 2004,91 (4) : 725-731.
  • 7Kyriakopoulou LG, Yousef GM, Scorilas A,et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer [J]. Clin Bio Chem, 2003, 36(2):135-143.
  • 8Yousef GM,Diamandis EP. The new human tissue kallikrein gene family:structure,function,and association to disease[J]. Endo Rev,2001,22(2) : 184-204.
  • 9Bayani J,Paliouras M,Planque C,et al. Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer[J]. Mol Oncol, 2008,2(3) :250-260.
  • 10Fung - Kee - Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer[J]. Curr Oncol, 2007, 14(5): 195.

共引文献30

同被引文献20

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部